CureSkin revenue grows 27.9% to Rs 133 crore in FY26, losses shrink 48.5%

Revenue growth and narrowing losses

CureSkin, a Bengaluru-based startup offering personalised skincare and haircare solutions through digital consultations and products, reported a 27.9% increase in operating revenue to Rs 133 crore for the financial year ending March 31, 2026, according to Entrackr. The company also reduced its net loss by 48.5% to Rs 35 crore from Rs 68 crore in FY25.

Product sales contributed 91% of the operating revenue, growing 17.1% to Rs 120.6 crore. Revenue from services surged nearly ninefold to Rs 12.4 crore, while other income added Rs 1 crore, bringing total revenue to Rs 134 crore.

The company’s EBITDA margin improved to -21.81% in FY26 from -60.94% in the previous fiscal year, reflecting better cost management.

Cost management drives financial improvement

CureSkin’s financial turnaround was supported by a 17.6% reduction in advertising and promotional spend, which fell to Rs 61 crore in FY26. Employee benefit expenses also declined by 5.3% to Rs 23.6 crore, while legal and professional charges dropped 36.5% to Rs 7.2 crore.

However, the cost of materials consumed increased by 15.4% to Rs 42 crore, and transportation expenses rose 30% to Rs 13 crore. Miscellaneous expenses grew 14.8% to Rs 22.2 crore.

Overall, the company spent Rs 1.27 to earn each rupee of operating revenue in FY26, down from Rs 1.69 in FY25.

Funding and liquidity

CureSkin has raised $26 million to date, including a $20 million round led by HealthQuad, with participation from JSW, Khosla Ventures, and Sharrp Ventures.

As of March 2026, the company had Rs 8 crore in cash and bank balances, with current assets totaling Rs 40 crore.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

CureSkin’s financial performance in FY26 signals a shift toward operational efficiency in India’s healthtech and direct-to-consumer skincare space. The 27.9% revenue growth, driven largely by product sales, shows the company has built a stable customer base—critical for startups in a segment where trust and repeat purchases matter. The ninefold jump in services revenue, though still a small share of total income, suggests early traction in diversifying beyond physical products.

The 48.5% reduction in net losses and improved EBITDA margin are likely to reassure investors, especially as funding for consumer-facing startups remains selective. CureSkin’s ability to cut advertising spend without sacrificing growth contrasts with the aggressive customer acquisition strategies common in e-commerce. For founders in healthtech or D2C, the startup’s cost discipline—particularly in ad spend and employee benefits—offers a playbook for extending runway without heavy layoffs.

However, the rising costs of materials and logistics could pressure margins if the company scales further. The next phase for CureSkin will hinge on whether it can maintain product demand while growing its services business, which may require a different operational playbook. For competitors or peers in dermatology or personal care, this report underscores the importance of balancing product-led growth with high-margin service offerings.

Related on Lazyfounder

• Khosla Ventures
• Sharrp Ventures
• More startup news